Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
2023 ASCO Genitourinary Cancers Symposium: a focus on urothelial carcinoma.
Cigliola A, Beccia V, Anghelone A, Panebianco M, Ciccarese C, Iacovelli R. Cigliola A, et al. Among authors: anghelone a. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1123-1126. doi: 10.1080/14737140.2023.2265570. Epub 2023 Oct 27. Expert Rev Anticancer Ther. 2023. PMID: 37781991
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C, Calegari MA, Basso M, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Chilelli MG, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: anghelone a. Curr Oncol. 2023 Jun 4;30(6):5456-5469. doi: 10.3390/curroncol30060413. Curr Oncol. 2023. PMID: 37366896 Free PMC article.
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Salvatore L, Bensi M, Vivolo R, Zurlo IV, Dell'Aquila E, Grande R, Anghelone A, Emiliani A, Citarella F, Calegari MA, Ribelli M, Basso M, Pozzo C, Tortora G. Salvatore L, et al. Among authors: anghelone a. Front Oncol. 2023 Feb 21;13:1125013. doi: 10.3389/fonc.2023.1125013. eCollection 2023. Front Oncol. 2023. PMID: 36895480 Free PMC article.
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
Signorelli C, Chilelli MG, Giannarelli D, Basso M, Calegari MA, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Morelli C, Dell'Aquila E, Cosimati A, Gemma D, Ribelli M, Emiliani A, Corsi DC, Arrivi G, Mazzuca F, Zoratto F, Morandi MG, Santamaria F, Saltarelli R, Ruggeri EM. Signorelli C, et al. Among authors: anghelone a. Cancers (Basel). 2023 Dec 8;15(24):5758. doi: 10.3390/cancers15245758. Cancers (Basel). 2023. PMID: 38136304 Free PMC article.
Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis.
Schietroma F, Anghelone A, Valente G, Beccia V, Caira G, Spring A, Trovato G, Di Bello A, Ceccarelli A, Chiofalo L, Perazzo S, Bensi M, Minucci A, Urbani A, Larocca LM, Basso M, Pozzo C, Salvatore L, Calegari MA, Tortora G. Schietroma F, et al. Among authors: anghelone a. Cancers (Basel). 2024 Feb 29;16(5):988. doi: 10.3390/cancers16050988. Cancers (Basel). 2024. PMID: 38473349 Free PMC article.
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. Maffezzoli M, et al. Among authors: anghelone a. Clin Exp Metastasis. 2024 Apr;41(2):117-129. doi: 10.1007/s10585-024-10266-6. Epub 2024 Feb 16. Clin Exp Metastasis. 2024. PMID: 38363410 Free PMC article.
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report.
Calegari MA, Stefano BD, Basso M, Carbone C, Camarda F, Ribelli M, Anghelone A, Vivolo R, Bensi M, Martini M, Pozzo C, Vellone M, Ardito F, Salvatore L, Giuliante F, Tortora G. Calegari MA, et al. Among authors: anghelone a. Clin Colorectal Cancer. 2021 Dec;20(4):364-367. doi: 10.1016/j.clcc.2021.09.002. Epub 2021 Sep 15. Clin Colorectal Cancer. 2021. PMID: 34629317 No abstract available.
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis.
Basso M, Signorelli C, Calegari MA, Lucchetti J, Zurlo IV, Dell'Aquila E, Arrivi G, Zoratto F, Santamaria F, Saltarelli R, Trovato G, Caira G, Angotti L, Schirripa M, Anghelone A, Schietroma F, Chilelli MG, Salvatore L, Pozzo C, Tortora G. Basso M, et al. Among authors: anghelone a. Target Oncol. 2024 Apr 13. doi: 10.1007/s11523-024-01050-3. Online ahead of print. Target Oncol. 2024. PMID: 38613732